Teva Pharmaceuticals Stock Surges on Wall Street, CFO Optimistic About Further Gains
תומצת מתוך TheMarker על ידי baba
Teva Pharmaceuticals is shifting its strategy to prioritize innovative drugs over generics, aiming for 20%-25% of sales from innovative drugs by the end of 2026. CFO Eli Kalif announced the accelerated change after the company's third-quarter 2026 financial reports. Teva's stock surged on Wall Street, with a target price between $48 and $52, and potential for further gains.
הידיעה ב-5 שורות · תקציר של baba
- Teva Pharmaceuticals is accelerating its strategic shift to focus on innovative drugs over generics.
- The company aims for innovative drugs to constitute 20%-25% of sales by the end of 2026.
- CFO Eli Kalif announced the strategic shift following the release of Q3 2026 financial reports.
- Teva's stock surged on Wall Street, with a target price between $48 and $52.
- The CFO expressed optimism that the stock could climb an additional 10%.
Teva Pharmaceuticals is accelerating its strategic shift towards focusing on innovative drugs over generics, according to CFO Eli Kalif. Speaking on Tuesday after the company released its third-quarter 2026 financial reports, Kalif stated that the sales mix is changing significantly. In 2022, innovative drugs accounted for 10% of Teva's sales, with generics making up 90%. The company aims to increase the proportion of innovative drugs to 20%-25% by the end of 2026, with the remaining sales from generics. Kalif indicated that this transition might become more pronounced in the coming years.
Following these statements, Teva's stock experienced a surge on Wall Street. The target price set for the company's shares ranges between $48 and $52, with the potential for an additional 10% increase.
לא אותו אירוע: ידיעות אחרות שחולקות עם הידיעה הזו אנשים, מקומות או נושא. רקע, תגובות והמשכים.
